These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 9166128)

  • 1. Experimental exposure of male volunteers to N-methyl-2-pyrrolidone (NMP): acute effects and pharmacokinetics of NMP in plasma and urine.
    Akesson B; Paulsson K
    Occup Environ Med; 1997 Apr; 54(4):236-40. PubMed ID: 9166128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological monitoring of N-methyl-2-pyrrolidone using 5-hydroxy-N-methyl-2-pyrrolidone in plasma and urine as the biomarker.
    Akesson B; Jönsson BA
    Scand J Work Environ Health; 2000 Jun; 26(3):213-8. PubMed ID: 10901113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levels of N-methyl-2-pyrrolidone (NMP) and its metabolites in plasma and urine from volunteers after experimental exposure to NMP in dry and humid air.
    Carnerup MA; Spanne M; Jönsson BA
    Toxicol Lett; 2006 Apr; 162(2-3):139-45. PubMed ID: 16321482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human experimental exposure to N-methyl-2-pyrrolidone (NMP): toxicokinetics of NMP, 5-hydroxy- N-methyl-2-pyrrolidone, N-methylsuccinimide and 2-hydroxy- N-methylsuccinimide (2-HMSI), and biological monitoring using 2-HMSI as a biomarker.
    Jönsson BA; Akesson B
    Int Arch Occup Environ Health; 2003 May; 76(4):267-74. PubMed ID: 12684812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human experimental exposure study on the uptake and urinary elimination of N-methyl-2-pyrrolidone (NMP) during simulated workplace conditions.
    Bader M; Wrbitzky R; Blaszkewicz M; van Thriel C
    Arch Toxicol; 2007 May; 81(5):335-46. PubMed ID: 17103143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-methylsuccinimide in plasma and urine as a biomarker of exposure to N-methyl-2-pyrrolidone.
    Jönsson BA; Akesson B
    Int Arch Occup Environ Health; 2001 May; 74(4):289-94. PubMed ID: 11401022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human volunteer study on the influence of exposure duration and dilution of dermally applied N-methyl-2-pyrrolidone (NMP) on the urinary elimination of NMP metabolites.
    Keener SA; Wrbitzky R; Bader M
    Int Arch Occup Environ Health; 2007 Feb; 80(4):327-34. PubMed ID: 16897094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dermal absorption and urinary elimination of N-methyl-2-pyrrolidone.
    Bader M; Keener SA; Wrbitzky R
    Int Arch Occup Environ Health; 2005 Sep; 78(8):673-6. PubMed ID: 16001206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contribution of CYP2E1 to N-methyl-2-pyrrolidone metabolism.
    Ligocka D; Lison D; Haufroid V
    Arch Toxicol; 2003 May; 77(5):261-6. PubMed ID: 12734639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Major metabolic pathway for N-methyl-2-pyrrolidone in humans.
    Akesson B; Jönsson BA
    Drug Metab Dispos; 1997 Feb; 25(2):267-9. PubMed ID: 9029058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ambient monitoring and biomonitoring of workers exposed to N-methyl-2-pyrrolidone in an industrial facility.
    Bader M; Rosenberger W; Rebe T; Keener SA; Brock TH; Hemmerling HJ; Wrbitzky R
    Int Arch Occup Environ Health; 2006 May; 79(5):357-64. PubMed ID: 16362322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemosensory effects during acute exposure to N-methyl-2-pyrrolidone (NMP).
    van Thriel C; Blaszkewicz M; Schäper M; Juran SA; Kleinbeck S; Kiesswetter E; Wrbitzky R; Stache J; Golka K; Bader M
    Toxicol Lett; 2007 Dec; 175(1-3):44-56. PubMed ID: 17981408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of exposure biomarkers from percutaneous absorption of N-methyl-2-pyrrolidone.
    Akesson B; Carnerup MA; Jönsson BA
    Scand J Work Environ Health; 2004 Aug; 30(4):306-12. PubMed ID: 15458014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human volunteer study on the inhalational and dermal absorption of N-methyl-2-pyrrolidone (NMP) from the vapour phase.
    Bader M; Wrbitzky R; Blaszkewicz M; Schäper M; van Thriel C
    Arch Toxicol; 2008 Jan; 82(1):13-20. PubMed ID: 17721780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concentrations of N-methyl-2-pyrrolidone (NMP) and its metabolites in plasma and urine following oral administration of NMP to rats.
    Carnerup MA; Saillenfait AM; Jönsson BA
    Food Chem Toxicol; 2005 Sep; 43(9):1441-7. PubMed ID: 15951091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative risk analysis for N-methyl pyrrolidone using physiologically based pharmacokinetic and benchmark dose modeling.
    Poet TS; Kirman CR; Bader M; van Thriel C; Gargas ML; Hinderliter PM
    Toxicol Sci; 2010 Feb; 113(2):468-82. PubMed ID: 19875680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dermal exposure to aqueous solutions of N-methyl pyrrolidone.
    Akrill P; Cocker J; Dixon S
    Toxicol Lett; 2002 Aug; 134(1-3):265-9. PubMed ID: 12191887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue distribution and excretion of N-methyl-2-pyrrolidone in male and female rats.
    Sitarek K; Kilanowicz A
    Int J Occup Med Environ Health; 2006; 19(2):142-8. PubMed ID: 17128812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolites of the alkyl pyrrolidone solvents NMP and NEP in 24-h urine samples of the German Environmental Specimen Bank from 1991 to 2014.
    Ulrich N; Bury D; Koch HM; Rüther M; Weber T; Käfferlein HU; Weiss T; Brüning T; Kolossa-Gehring M
    Int Arch Occup Environ Health; 2018 Nov; 91(8):1073-1082. PubMed ID: 30167791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological monitoring and health effects of low-level exposure to N-methyl-2-pyrrolidone: a cross-sectional study.
    Haufroid V; Jaeger VK; Jeggli S; Eisenegger R; Bernard A; Friedli D; Lison D; Hotz P
    Int Arch Occup Environ Health; 2014 Aug; 87(6):663-74. PubMed ID: 24078144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.